glp-1 mcas A newly published case series reports that receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or GLP-1 Receptor Agonists, MCAS and

These findings support the cardioprotective benefits of independent SGLT-2i and GLP-1 RAs regardless of baseline metformin use

Radbill 2008

My name's Dr Mike and I'm going to tell you in 30 seconds all you need to know about peptides that people are using for anti-aging and skin health s" TikTok1.2M views @silkroadessentials's GHK-Cu hair claims, fact-checked @silkroadessentials "Hi, I'm GHK-Cu but just call me Copper

A one-month trial may produce initial appetite suppression, yet most clinical evidence supports longer treatment windows to see significant, stable weight reduction and metabolic benefits

The American College of Cardiology's 2024 expert consensus statement on anticoagulation management notes: "Patients initiating GLP-1 receptor agonists who are on warfarin should be treated as though a new interacting medication has been added, with INR rechecked at short intervals until stability is confirmed" [10]